Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells.

BACKGROUND The prognosis of advanced or recurrent colorectal cancer is still poor. Dye-effluxing side population (SP) colon cancer cells are reportedly resistant to chemotherapeutic agents. Most sporadic colorectal cancers involve constitutive activation of the Wnt signaling pathway. In this study, we examined the effect of the Wnt signaling on SP cells and the possibility that inhibition of Wnt signaling may decrease the resistance to chemotherapeutic drugs in the human colon cancer cells. MATERIALS AND METHODS Drug resistance of SP cells to 5-fluorouracil (5-FU) and irinotecan, decrease of SP cells by the Wnt signaling inhibition and activation of the Wnt signaling of the sorted SP cells were examined using the SW480 colon cancer cell line. mRNA expressions of ATP-binding cassette (ABC) transporters when Wnt signaling was inhibited were evaluated with real-time PCR using colon cancer cell lines (SW480, DLD-1, HCT116, HT29 and LOVO). The sensitivity to irinotecan and paclitaxel when the Wnt signaling was inhibited was investigated using SW480. Inhibition of Wnt signaling was performed by siRNA of beta-catenin. RESULTS SP cells showed more resistance to 5-FU and irinotecan, and higher activation of the Wnt signaling pathway, than non-SP cells. Silencing of beta-catenin decreased significantly more SP cells than non-SP cells. Expression of ABC transporter genes, such as ABCB1 and ABCG2, was significantly higher in SP cells than non-SP cells. Silencing of beta-catenin decreased transcription of these ABC transporter genes; beta-catenin-silenced cells became relatively sensitive to paclitaxel and irinotecan. CONCLUSION These results indicate that inhibiting the Wnt signaling pathway may be a fruitful strategy for targeting chemotherapy-resistant colon cancer cells, including SP cells.

[1]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[2]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[3]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[4]  B. Alman,et al.  Side population cells in human cancers. , 2008, Cancer letters.

[5]  J. Beckmann,et al.  The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway , 2009, Oncogene.

[6]  I. Tomlinson,et al.  Colorectal cancer and genetic alterations in the Wnt pathway , 2006, Oncogene.

[7]  S. Hirohashi,et al.  Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. , 2000, Cancer research.

[8]  N. Wright,et al.  Side populations of gastrointestinal cancers are not enriched in stem cells , 2008, The Journal of pathology.

[9]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[10]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[11]  Haruo Tanaka,et al.  The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. , 2009, Anticancer research.

[12]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[13]  M. Dean,et al.  The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[15]  E. Van Cutsem,et al.  Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice? , 2005, JAMA.

[16]  T. Utsunomiya,et al.  Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System , 2006, Stem cells.

[17]  P. Polakis.  Wnt signaling and cancer. , 2000, Genes & development.

[18]  L. Mishra,et al.  New therapeutics targeting colon cancer stem cells , 2009, Current colorectal cancer reports.

[19]  H. Clevers,et al.  APC, Signal transduction and genetic instability in colorectal cancer , 2001, Nature Reviews Cancer.

[20]  S. Bates,et al.  ABCG2: determining its relevance in clinical drug resistance , 2007, Cancer and Metastasis Reviews.

[21]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[22]  I. Pastan,et al.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Wendy S. Wright,et al.  Wnt Signaling Protects 3T3-L1 Preadipocytes from Apoptosis through Induction of Insulin-like Growth Factors* , 2002, The Journal of Biological Chemistry.

[24]  B. Luo,et al.  A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. , 2009, Neoplasma.

[25]  R. Schneider-Broussard,et al.  Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. , 2005, Cancer research.

[26]  V. Ling.  Multidrug Resistance and P‐Glycoprotein Expression , 1987, Annals of the New York Academy of Sciences.

[27]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[28]  Louis Gaboury,et al.  SP analysis may be used to identify cancer stem cell populations. , 2006, Experimental cell research.

[29]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[30]  A. S. Conner,et al.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo , 1996, The Journal of experimental medicine.

[31]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[32]  Shi-Yong Sun,et al.  Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the Non-SP, a higher expression of c-Myc and TRAIL-receptor DR4 , 2007, Cancer biology & therapy.

[33]  W. Hait,et al.  Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. , 2003, Cancer research.

[34]  S. Hladky,et al.  Activation of β‐catenin signalling by GSK‐3 inhibition increases p‐glycoprotein expression in brain endothelial cells , 2008, Journal of neurochemistry.

[35]  Kiyoko Kato,et al.  Characterization of side-population cells in human normal endometrium. , 2007, Human reproduction.

[36]  T. Lu,et al.  Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. , 2003, BioTechniques.

[37]  Margaret Robertson,et al.  Identification and characterization of the familial adenomatous polyposis coli gene , 1991, Cell.

[38]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[39]  H. Clevers,et al.  Linking Colorectal Cancer to Wnt Signaling , 2000, Cell.